News

Treatment with Signifor (pasireotide) for one year reduces the risk for heart disease and diabetes in patients with Cushing’s disease, by improving visceral adiposity index (VAI) scores and adipose tissue dysfunction, according to a multi-center study. However, Signifor did not prevent an increase in cases of diabetes, or change heart disease risk…

Stereotactic radiosurgery – a type of targeted, high-dose radiation therapy – delivered with CyberKnife technology effectively induces remission in Cushing’s disease patients whose condition persisted after surgical removal of their pituitary glands. However, researchers advise, caution when interpreting the findings. While promising, the study included only a small group of patients analyzed retrospectively.

Strongbridge Biopharma is expecting a second patent on its Cushing’s syndrome therapy Recorlev (levoketoconazole). The signal it received was the U.S. Patent and Trademark Office completing a review of its new patent application for the cortisol synthesis inhibitor. The second patent, which would expire Jan. 10, 2026, would cover other conditions in…